Table 3 Correlation between the deposition of IgG subclasses along GBM and the clinical and pathological parameters of patients
| Â | IgG1 | IgG2 | IgG3 | IgG4 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Positive (n=9) | Negative (n=37) | P | Positive (n=22) | Negative (n=24) | P | Strong/Linear (n=7) | Weak/Segmental (n=39) | P | Positive (n=7) | Negative (n=39) | P | |
Age (years) | 38.8±13.8 | 34.5±16.2 | 0.286 | 38.1±15.6 | 32.7±15.7 | 0.202 | 37.6±10.4 | 34.9±16.6 | 0.320 | 31.4±16.1 | 36±15.7 | 0.529 |
Gender (male/female) | 5/4 | 27/10 | 0.308 | 15/7 | 17/7 | 0.845 | 5/2 | 27/12 | 0.907 | 6/1 | 26/13 | 0.313 |
Hydrocarbon exposure, n (%) | 1/9 (11.1%) | 2/35 (5.7%) | 0.567 | 1/21 (4.8%) | 2/23 (8.7%) | 0.605 | 1/7 (14.3%) | 2/37 (5.4%) | 0.393 | 0/7 (0%) | 3/37 (8.1%) | 0.435 |
Prodromal infection, n (%) | 6/9(66.7%) | 13/37 (35.1%) | 0.085 | 8/22 (36.4%) | 11/24 (45.8%) | 0.515 | 3/7 (42.9%) | 16/39 (41.0%) | 0.928 | 2/7 (28.6%) | 17/39 (43.6%) | 0.457 |
Smoking, n (%) | 4/8 (50%) | 20/37 (54.1%) | 0.835 | 12/21 (57.1%) | 12/24 (50%) | 0.632 | 4/7 (57.1%) | 20/38 (52.6%) | 0.826 | 4/7 (57.1%) | 20/8 (52.6%) | 0.826 |
Gross hematuria, n (%) | 2/9 (22.2%) | 13/37 (35.1%) | 0.459 | 9/22 (40.9%) | 6/24 25%) | 0.250 | 0/7 (0%) | 15/39 (38.5%) | 0.046 | 3/7 (42.9%) | 12/39 (30.8%) | 0.530 |
Nephrotic syndrome, n (%) | 3/5(60.0%) | 16/26 (61.5%) | 0.948 | 8/14 (57.1%) | 11/17 (64.7%) | 0.667 | 4/6 (66.7%) | 15/25 (60%) | 0.763 | 4/5 (80%) | 15/26(57.7%) | 0.348 |
Hemoglobin (g/L) | 94±28.5 | 83.5±25.2 | 0.493 | 90.6±24.2 | 80.9±27.6 | 0.146 | 105.1±25.8 | 82.0±24.9 | 0.038 | 84.3±29.7 | 85.9±25.9 | 0.818 |
Oliguria/anuria, n (%) | 3/9(33.3%) | 11/37 (29.7%) | 0.833 | 7/22 (31.8%) | 7/24 (29.2%) | 0.845 | 0/7 (0%) | 14/39 (35.9%) | 0.057 | 2/7 (28.6%) | 12/39 (30.8%) | 0.907 |
Serum creatinine at presentation (μmol/L) | 503.8±341.9 | 783.2±371.0 | 0.031 | 674.9±373.7 | 777.8±384.6 | 0.350 | 445.4±333.0 | 779.4±367.4 | 0.028 | 825±532.6 | 711.2±350.8 | 0.490 |
Anti-GBM antibodies (U/mL) | 56.1±34.9 | 69.7±40.8 | 0.359 | 90.6±24.2 | 80.9±27.6 | 0.452 | 39.8±42.9 | 70±38.7 | 0.060 | 64.5±59.5 | 67.4±36.3 | 0.566 |
ANCA, n (%) | 2/9 (22.2%) | 7/37 (18.9%) | 0.823 | 4/18 (22.2%) | 5/24 (20.8%) | 0.821 | 0/9 (0%) | 9/39 (23.1%) | 0.156 | 2/7 (28.6%) | 7/39 (17.9%) | 0.514 |
Percentage of total crescents (%) | 60.6±44.3 | 832±23.6 | 0.397 | 76.4±30.1 | 81.0±29.7 | 0.587 | 54.7±47.0 | 83.1±23.8 | 0.183 | 68.9±38.7 | 80.5±28 | 0.719 |
Cellular crescents (%) | 43.3±36.1 | 64.5±32.3 | 0.086 | 65.3±34.0 | 55.8±33.6 | 0.285 | 39.6±34.8 | 64.0±32.6 | 0.093 | 58.9±38.6 | 60.6±33.4 | 1 |
Fibrotic crescents (%) | 34.5±32.9 | 32.8±30.9 | 0.892 | 25.6±27.9 | 40.1±32.5 | 0.113 | 31.8±30.8 | 33.4±31.4 | 0.858 | 41.1±38.6 | 31.7±29.8 | 0.590 |
C3 deposits (median) | 2 | 1 | 1.000 | 0 | 1 | 0.627 | 2 | 1 | 0.131 | 2 | 1 | 0.131 |
Ultrastructrual lesions | 2 | 2 | 0.438 | 2 | 2 | 0.727 | 2 | 2 | 0.438 | 2 | 2 | 0.438 |
Renal survival (1Â year), n (%) | 3/9 (33.3%) | 7/37 (18.9%) | 0.347 | 5/22 (22.7%) | 5/24 (20.8%) | 0.876 | 4/7 (57.1%) | 7/39 (17.9%) | 0.141 | 1/7 (14.3%) | 9/39 (23.1%) | 0.604 |
Patient survival (1Â year), n (%) | 6/9 (66.7%) | 30/37 (81.1%) | 0.347 | 17/22 (77.3%) | 19/24 (79.2%) | 0.876 | 7/7 (100%) | 29/39 (74.4%) | 0.130 | 4/7 (57.1%) | 32/39 (82.1%) | 0.141 |